Abstract |
We report hypersensitivity reactions associated with fidaxomicin, an antibacterial drug approved for the treatment of Clostridium difficile-associated diarrhea. These reactions are viewed as significant because of severity and unexpected because fidaxomicin is minimally absorbed. The fidaxomicin labeling was revised to include information about the possibility of hypersensitivity reactions.
|
Authors | Dmitri E Iarikov, John Alexander, Sumathi Nambiar |
Journal | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
(Clin Infect Dis)
Vol. 58
Issue 4
Pg. 537-9
(Feb 2014)
ISSN: 1537-6591 [Electronic] United States |
PMID | 24178248
(Publication Type: Journal Article)
|
Chemical References |
- Aminoglycosides
- Anti-Bacterial Agents
- Fidaxomicin
|
Topics |
- Adult
- Aged
- Aminoglycosides
(adverse effects, therapeutic use)
- Anti-Bacterial Agents
(adverse effects, therapeutic use)
- Clostridioides difficile
(isolation & purification)
- Clostridium Infections
(drug therapy, microbiology)
- Diarrhea
(drug therapy, microbiology)
- Drug Hypersensitivity
- Female
- Fidaxomicin
- Humans
- Male
- Middle Aged
|